Prognostic tool for Hepatocellular carcinoma
For more info, please see the links:
Liver Cancer
Liver cancer ranks as the 6th most common cancer and the 3rd leading cause of cancer-related death worldwide. In 2022 alone, 866.136 new cases of liver cancer were diagnosed, and 758.725 deaths occurred due to the disease. By 2050, liver cancer incidence is predicted to increase globally, with 1.52 million new cases, and mortality rates could rise by 80.5%, reaching more than 1 million deaths.
Hepatocellular carcinoma (HCC) accounts for 90% of liver cancer cases and for 75% of liver cancer deaths. Key risk factors for HCC include environmental factors such as alcohol consumption and aflatoxin exposure, chronic infections with hepatitis B (HBV) or C (HCV), diabetes, and obesity linked to metabolic dysfunction-associated steatohepatitis (MASH).
HCC staging and treatment
The Barcelona Clinic Liver Cancer (BCLC) staging and treatment system is the most widely used framework for classifying HCC.
Liver transplantation remains the most effective curative option for patients with early to intermediate-stage HCC and is the second most common solid organ transplantation globally.
However, only a fraction of the global demand for liver transplants is met due to limited organ availability. As a result, strict and rigorous clinical criteria are required to better select patients that will benefit from this type of treatment.
HepatoPredict
HepatoPredict is an innovative medical decision tool aimed at determining the prognosis of HCC in the context of liver transplantation. In doing so, it helps medical teams make better decisions either by selecting patients more accurately for liver transplantation or defining better patient monitoring strategies pre- or post-surgery.
HepatoPredict addresses the expression level of 4 genes at tumour level by RT-qPCR. This gene expression signature and three clinical variables are integrated through a predictive algorithm. HepatoPredict outputs prognostic information in the form of a simple and objective clinical report classifying patients based on the likelihood of disease recurrence.
HepatoPredict should be used in conjunction with standard laboratory and clinical assessments, consistent with established practices. HepatoPredict does not endorse any specific laboratory or clinical measure; rather, it should be integrated with local clinical standards for comprehensive patient evaluation.
Who is it for?
We developed HepatoPredict to support hepatologists, hepatobiliary surgeons and multidisciplinary teams in deciding on the best therapeutical approach for a patient with HCC.
HepatoPredict empowers healthcare teams with clear prognostic information to:
Availability
Contact us about other locations via info@ophiomics.com
If you are a distributor and are interested in representing our product contact us via info@ophiomics.com
References
- Globoscan 2022, WHO
- Lovet et al (2021) Hepatocellular carcinoma. Nature Reviews. doi: 10.1038/s41572-020-00240-3
- Pinto-Marques and Cardoso et al (2022) A gene expression signature to select hepatocellular carcinoma patients for liver transplantation. Annals of Surgery. doi: 10.1097/SLA.0000000000005637
- Gonçalves-Reis M et al (2024) Analytical validation and algorithm improvement of HepatoPredict kit to assess hepatocellular carcinoma prognosis before a liver transplantation. Pract Lab Med. 2024 Feb 5;39:e00365. doi: 10.1016/j.plabm.2024.e00365.
- Reig M et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.